CERo Therapeutics Holdings, Inc. (CERO) company profile
Close on Oct 19, 2026Market cap $253.05KP/E –Yield 172833.33%
About CERo Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
CERo Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing genetically engineered cellular immunotherapies for cancer treatment. The company designs Chimeric Engulfment Receptor T cell therapies, known as CER-T cells, which integrate characteristics of innate and adaptive immune responses to target and eliminate cancer cells. Its primary product candidate in development is CER-1236. Because its candidate therapies remain in early clinical or preclinical stages, the company has not yet commercialized any therapies, meaning its potential future customers will consist of cancer patients and healthcare providers upon regulatory approval.
The company operates in the United States and has no commercial products or physical retail stores. It conducts its research and clinical development through third-party contract development and manufacturing organizations, contract research organizations, and suppliers. CERo Therapeutics maintains its principal executive offices and headquarters in South San Francisco, California.
Summary of the business section of CERo Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CERo Therapeutics Holdings, Inc.
- Headquarters
- South San Francisco, CA
- Address
- 201 Haskins Way, Suite 230 94080
- Phone
- (650) 407-2376
- Website
- cero.bio
- Employees
- 8, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Salberg & Company, P.A., Boca Raton, Florida
Stock & identifiers
- Ticker
- CERO
- Other tickers
- CEROW
- Former tickers
- PBAX until Feb 15, 2024
- Exchange
- OTC
- IPO date
- Oct 8, 2021
- Shares outstanding
- 72M, Aug 13, 2026
- Public float
- $11.24M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-20 reverse, Jun 13, 2025; 1-for-100 reverse, Jan 8, 2025
- SEC CIK
- 1870404
- CUSIP
- 71902K402
- ISIN
- US71902K4022
- FIGI
- BBG012LSLG64
- Share class FIGI
- BBG012LSLH99
- EIN
- 87-1088814
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Christopher B. Ehrlich | Chairman and CEO, Director | 11,091,654 |
| Kristen Pierce | Chief Development Officer | – |
| Andrew Albert Kucharchuk | Chief Financial Officer | – |
| Eric Francois | Director | – |
| Shami Patel | Director | 1,120,254 |
| Lindsey Rolfe | Director | – |
| Michael Byrnes | Director | – |
| Kathleen Laporte | Director | 989,325 |
| Brian G. Atwood | Director | 491,784 |
IPO
From the final prospectus (Form 424B4) and the first day of trading
SPAC offering
- Type
- SPAC (blank check) IPO of units
- Final prospectus filed
- Oct 8, 2021
- Offer price
- $10.00
- Securities offered
- 15,500,000
- Gross proceeds
- $155.00M
- Exchange
- Nasdaq
- First trading day
- Nov 30, 2021
- First-day close
- $9.93-0.7%
- Lock-up ends (est.)
- May 29, 2022
“Each unit has an offering price of $10.00 and consists of one share of our Class A common stock and one-half of one warrant.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had eight full-time employees, including two executive officers and six employees conducting Research and Development.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?